Celldex Therapeutics, Inc. CLDX

When biopharmaceutical companies advance platform technologies targeting complex immunological pathways, market participants must weigh clinical efficacy against the heavy capital requirements of drug development. Celldex Therapeutics (NASDAQ:CLDX) embodies the classic profile of a clinical-stage innovator: a proprietary mast cell inhibitor platform, a robust balance sheet insulated by substantial cash reserves, and multi-indication optionality across severe […]

H.C. Wainwright called the Phase 3 results a “compelling” late-stage assessment of Barzolvolimab in a patient population with a significant unmet need.

Celldex Therapeutics (NASDAQ:CLDX) shares gained 8% on Tuesday after the company reported positive topline results from two Phase 3 trials evaluating barzolvolimab in patients with chronic spontaneous urticaria (CSU). Both EMBARQ-CSU1 and EMBARQ-CSU2 met their primary endpoints and all key secondary endpoints, demonstrating statistically significant improvements in disease activity compared with placebo.

Celldex Therapeutics' (CLDX) two Phase 3 trials of barzolvolimab in patients with chronic spontaneou

Best-in-disease results showed rapid, profound, sustained efficacy, supporting barzolvolimab’s potential to be a transformational therapy in CSUEMBARQ-CSU1 and -CSU2 met primary and all key secondary endpoints at 12 weeks across both studies and both dose groups Clinically meaningful and statistically significant benefit demonstrated in omalizumab refractory CSU and patients with severe disease or severe angioedema Efficacy sustained or deepened from weeks 12 to 24 Well tolerated with a favorabl

HAMPTON, N.J., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today that management will participate in a fireside chat at the upcoming Cantor Global Healthcare Conference on September 10, 2026 at 8:00am ET. The webcast of the presentation will be available on the “Events and Presentations” page of the “Investors” section of the Celldex Website. Replays will be available for 90 days following the event. About CelldexCelldex is pioneering new horizons in immunology to deliver

Celldex Therapeutics (CLDX) released its second quarter 2026 results on 6 August, reporting very limited revenue and a wider net loss. This places the stock’s recent strength in sharper focus for investors. See our latest analysis for Celldex Therapeutics. Celldex Therapeutics shares have climbed strongly over the past year, with a year to date share price return of 54.42% and a 1 year total shareholder return of 101.89%. The recent 90 day share price gain of 29.21% suggests momentum has been...

Celldex Therapeutics, Inc. recently reported second-quarter 2026 results, with revenue falling to US$0.022 million and net loss widening to US$73.5 million, while loss per share from continuing operations increased to US$0.94. Over the first half of 2026, revenue slipped to just US$0.037 million as the company’s net loss rose to US$152.19 million, highlighting the cost intensity of its operations relative to minimal reported revenue. We will examine how this widening net loss and sharply...

Celldex Therapeutics stock has more than doubled over the past year, yet its broader valuation checks lean expensive rather than cheap, which raises questions about how much of its pipeline story is already reflected in the current price. The share price has returned 101.9% over the past year, which sets a high bar for any further upside to be justified by future execution. Progress in Celldex Therapeutics' allergy and immunology programs, including ongoing late stage studies and early...

Celldex Therapeutics (NasdaqCM:CLDX) reported updated clinical pipeline data, including positive Phase 1 results for bispecific antibody CDX-622. The company outlined progress on ongoing Phase 3 studies for barzolvolimab following its latest development review. Celldex discontinued its Phase 2 trial in prurigo nodularis after the program did not show sufficient efficacy. For readers who want to see more stock ideas linked to similar healthcare themes, the next step is to explore 43...

Celldex (CLDX) delivered earnings and revenue surprises of +9.62% and -98.75%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Barzolvolimab Phase 3 chronic spontaneous urticaria studies (EMBARQ-CSU 1 and 2) ongoing, topline data expected in Sept/Oct 2026; BLA submission planned for 2027Phase 3 barzolvolimab cold urticaria and symptomatic dermographism study (EMBARQ-ColdU and -SD) actively enrolling; Phase 2 topline data in AD expected in late 2026 Positive results from Phase 1 trial of bispecific CDX-622 showed rapid, profound, dose-dependent reductions in serum tryptase and CDX-622 was well tolerated; Phase 1 CDX-622